<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Arq Bras Cardiol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Arq. Bras. Cardiol</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25884774</article-id>
      <article-id pub-id-type="pmc">4386857</article-id>
      <article-id pub-id-type="doi">10.5935/abc.20140198</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Left Ventricular Assist Device Followed by Heart
Transplantation</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Biselli</surname>
            <given-names>Bruno</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
          <xref ref-type="corresp" rid="c01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ayub-Ferreira</surname>
            <given-names>Silvia Moreira</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Avila</surname>
            <given-names>Monica Samuel</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gaiotto</surname>
            <given-names>F&#xE1;bio Antonio</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Jatene</surname>
            <given-names>Fabio Biscegli</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bocchi</surname>
            <given-names>Edimar Alcides</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
      </contrib-group>
      <aff id="aff01">Instituto do Cora&#xE7;&#xE3;o do Hospital das Cl&#xED;nicas da Faculdade de Medicina da
Universidade de S&#xE3;o Paulo, S&#xE3;o Paulo, SP &#x2013; Brazil</aff>
      <author-notes>
        <corresp id="c01"><bold>Mailing Address: Bruno Biselli</bold>, Av. Dr. Eneas de Carvalho
Aguiar, 44. Postal Code 05403-900, S&#xE3;o Paulo, SP - Brazil. E-mail:
<email>brunobiselli@globo.com.</email></corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <month>3</month>
        <year>2015</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <month>3</month>
        <year>2015</year>
      </pub-date>
      <volume>104</volume>
      <issue>3</issue>
      <fpage>e22</fpage>
      <lpage>e24</lpage>
      <history>
        <date date-type="received">
          <day>27</day>
          <month>2</month>
          <year>2014</year>
        </date>
        <date date-type="rev-recd">
          <day>02</day>
          <month>6</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>22</day>
          <month>7</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution NonCommercial License which permits unrestricted noncommercial
use, distribution, and reproduction in any medium provided the original work is
properly cited.</license-p>
        </license>
      </permissions>
      <kwd-group>
        <kwd>Heart Transplantation</kwd>
        <kwd>Heart-Assist Devices</kwd>
        <kwd>Heart Failure</kwd>
        <kwd>Shock, Cardiogenic</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>Introduction</title>
      <p>Heart failure (HF) is the major cause of cardiovascular hospitalization in
Brazil<sup><xref rid="r01" ref-type="bibr">1</xref></sup>. It is estimated that
approximately 1%&#x2013;2% of the population present with HF and 50% of these individuals have
a decreased ejection fraction<sup><xref rid="r02" ref-type="bibr">2</xref></sup>.</p>
      <p>In the last 30 years, despite the substantial improvement in the treatment of chronic
HF, the quality of life and survival rates of affected patients are limited. In
addition, most of these patients are refractory to standard treatment and
hospitalization, and rates of death or rehospitalization within 6 months are
approximately 50%<sup><xref rid="r02" ref-type="bibr">2</xref></sup>.</p>
      <p>Heart transplantation (HT) is considered the standard treatment in patients with
advanced or refractory HF. However, this procedure is limited by the number of available
donors and possible contraindications, such as pulmonary hypertension (PH) secondary to
HF<sup><xref rid="r03" ref-type="bibr">3</xref></sup>.</p>
      <p>Since 1994, after the approval of the use of implantable ventricular assist devices
(VADs) for long-term therapy in patients with advanced HF in the United States, there
has been an increased interest in these devices. Technological improvement of VADs has
resulted in the improved survival and quality of life in patients undergoing
implantation, and the limitations of HT render these devices as an important tool for
the treatment of advanced HF<sup><xref rid="r04" ref-type="bibr">4</xref>,<xref rid="r05" ref-type="bibr">5</xref></sup>.</p>
      <p>In Brazil, VAD therapy for patients with HF is still nascent. Here we report, to the
best of our knowledge, the first case of hospital discharge after VAD implantation and
subsequent HT. </p>
    </sec>
    <sec>
      <title>Case Report</title>
      <p>A 41-year-old male patient presented with HF symptoms and was diagnosed with idiopathic
dilated cardiomyopathy in 2008. Even after optimization of drug therapy, HF remained as
New York Heart Association (NYHA) functional class&#xA0;II. The patient had no other
comorbidities. In 2012, the patient experienced a progressive worsening of symptoms and
signs of HF in spite of therapy with enalapril, carvedilol, spironolactone, ivabradine,
digoxin, and furosemide. </p>
      <p>After being hospitalized for cardiogenic shock, the patient was started on intravenous
administration of inotropic and vasodilator agents. This resulted in the stabilization
of hemodynamic parameters, but the patient remained dependent on inotropic support
[Interagency Registry for Mechanically Circulatory Support (INTERMACS classification&#xA0;3).
The echocardiographic parameters at admission are detailed in <xref ref-type="table" rid="t01">Table 1</xref>. The evaluation for HT revealed the following findings: a
significant HF with pulmonary artery pressure (PAP) of 96&#xA0;&#xD7;&#xA0;33 (56) mmHg, transpulmonary
gradient of 25&#xA0;mmHg, and pulmonary vascular resistance of 6.5 Wood units, with little
response to systemic and pulmonary vasodilators. Thus HT was contraindicated and the
patient was then indicated for VAD therapy.</p>
      <table-wrap id="t01" orientation="portrait" position="float">
        <label>Table 1</label>
        <caption>
          <p>Pre-VAD implantation echocardiogram results</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr style="border-bottom-style:solid; border-bottom-width:thin">
              <th rowspan="1" colspan="1">&#xA0;</th>
              <th rowspan="1" colspan="1">&#xA0;</th>
              <th rowspan="1" colspan="1">&#xA0;</th>
              <th rowspan="1" colspan="1">&#xA0;</th>
              <th rowspan="1" colspan="1">Evaluation of the right ventricle</th>
              <th rowspan="1" colspan="1">&#xA0;</th>
              <th rowspan="1" colspan="1">Normal values</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">LA</td>
              <td align="center" rowspan="1" colspan="1">50 mm</td>
              <td align="center" rowspan="1" colspan="1">LVEF (Teicholz)</td>
              <td align="center" rowspan="1" colspan="1">24%</td>
              <td rowspan="1" colspan="1">Basal diameter</td>
              <td align="center" rowspan="1" colspan="1">45 mm</td>
              <td align="center" rowspan="1" colspan="1">&lt; 45 mm</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Septum</td>
              <td align="center" rowspan="1" colspan="1">8 mm</td>
              <td align="center" rowspan="1" colspan="1">FSLV</td>
              <td align="center" rowspan="1" colspan="1">11%</td>
              <td rowspan="1" colspan="1">Average diameter</td>
              <td align="center" rowspan="1" colspan="1">31 mm</td>
              <td align="center" rowspan="1" colspan="1">&lt; 35 mm</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">PW</td>
              <td align="center" rowspan="1" colspan="1">8 mm</td>
              <td align="center" rowspan="1" colspan="1">Mass Index</td>
              <td align="center" rowspan="1" colspan="1">128 g/m<sup>2</sup></td>
              <td rowspan="1" colspan="1">Longitudinal diameter</td>
              <td align="center" rowspan="1" colspan="1">72 mm</td>
              <td align="center" rowspan="1" colspan="1">&lt; 86 mm</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">LVDD</td>
              <td align="center" rowspan="1" colspan="1">71 mm</td>
              <td align="center" rowspan="1" colspan="1">Diastolic dysfunction</td>
              <td align="center" rowspan="1" colspan="1">Gade 3</td>
              <td rowspan="1" colspan="1">Sphericity index</td>
              <td align="center" rowspan="1" colspan="1">0.625</td>
              <td align="center" rowspan="1" colspan="1">&lt; 0.6</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">LVSD</td>
              <td align="center" rowspan="1" colspan="1">63 mm</td>
              <td align="center" rowspan="1" colspan="1">MR</td>
              <td align="center" rowspan="1" colspan="1">Important</td>
              <td rowspan="1" colspan="1">Variation in the RV fractional area</td>
              <td align="center" rowspan="1" colspan="1">26%</td>
              <td align="center" rowspan="1" colspan="1">&gt; 35%</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">LVDV</td>
              <td align="center" rowspan="1" colspan="1">264 ml</td>
              <td align="center" rowspan="1" colspan="1">TR</td>
              <td align="center" rowspan="1" colspan="1">Mild</td>
              <td rowspan="1" colspan="1">TAPSE (mm)</td>
              <td align="center" rowspan="1" colspan="1">17 mm</td>
              <td align="center" rowspan="1" colspan="1">&gt; 16 mm</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">LVSV</td>
              <td align="center" rowspan="1" colspan="1">201 ml</td>
              <td align="center" rowspan="1" colspan="1">SPAP</td>
              <td align="center" rowspan="1" colspan="1">72 mmHg</td>
              <td rowspan="1" colspan="1">S wave (cm/s)</td>
              <td align="center" rowspan="1" colspan="1">10 cm/s</td>
              <td align="center" rowspan="1" colspan="1">&gt; 10 cm/s</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn>
            <p>LA: left atrium; LVDD: left ventricular diastolic diameter; LVSD: left
ventricular systolic diameter; FSLV: fractional shortening of the left
ventricle; LVEF: left ventricular ejection fraction; MR: degree of mitral
regurgitation; TR: degree of tricuspid regurgitation; PW: posterior wall; SPAP:
estimated systolic pulmonary artery pressure; RV: right ventricle; LVDV: left
ventricular diastolic volume; LVSV; left ventricular systolic volume; TAPSE:
tricuspid annular plane systolic excursion</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>The patient had a few risk factors for right ventricular (RV) dysfunction, one of the
major early complications of VAD implantation. The central venous pressure was 15&#xA0;mmHg,
with mild tricuspid insufficiency. Echocardiographic evaluation (<xref ref-type="table" rid="t01">Table 1</xref>) showed no significant RV dilation, and the main parameters
used in the assessment of RV function [tricuspid annular plane systolic excursion
(TAPSE), fractional area change, and S&#x2019; wave] suggested a mild RV dysfunction. </p>
      <p>In August 2012, the patient underwent implantation of continuous-flow VAD (Berlin Heart
INCOR&#xAE;). The flow was approximately 5 L/min and the hemodynamic management was initially
performed with inotropic agents, vasopressors, nitric oxide, and diuretics/crystalloid
for adjustment of blood volume. The patient&#x2019;s hemodynamic parameters were stable
postoperatively. The anticoagulation regime administered to the patient involved
unfractionated heparin and antiplatelet therapy and was initiated early on the first
postoperative day. </p>
      <p>During the postoperative period, serial computed tomography examinations revealed that
the patient exhibited transient focal neurological deficit without evidence of
structural changes. In addition, the patient presented with pneumonia associated with
mechanical ventilation, need for prolonged intubation, and acute renal failure (ARF).
Therefore, he was subjected to transient renal replacement therapy. These complications
were fully reversed during recovery.</p>
      <p>Subsequently, HF therapy with enalapril, beta-blockers, loop diuretics, spironolactone,
and sildenafil was reintroduced. The patient was maintained on warfarin and antiplatelet
therapy with acetylsalicylic acid (ASA) and clopidogrel, and was discharged 137 days
after VAD implantation, without any functional dependence and in good clinical
condition. Sequential echocardiographic evaluations after VAD implantation showed no
worsening of RV function. In addition, we observed a significant decrease in the
systolic PAP during recovery (<xref ref-type="table" rid="t02">Table 2</xref>), which
eliminated the contraindication for HT. Eight months after VAD implantation, the patient
expressed desire to be listed for HT.</p>
      <table-wrap id="t02" orientation="portrait" position="float">
        <label>Table 2</label>
        <caption>
          <p>Evolution of pulmonary systolic pressure estimated by echocardiography</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th rowspan="1" colspan="1">Time</th>
              <th rowspan="1" colspan="1">Before implantation</th>
              <th rowspan="1" colspan="1">30 days after implantation</th>
              <th rowspan="1" colspan="1">90 days after implantation</th>
              <th rowspan="1" colspan="1">120 days after implantation</th>
              <th rowspan="1" colspan="1">280 days after implantation</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">SPAP (mmHg)</td>
              <td align="center" rowspan="1" colspan="1">72</td>
              <td align="center" rowspan="1" colspan="1">60</td>
              <td align="center" rowspan="1" colspan="1">58</td>
              <td align="center" rowspan="1" colspan="1">33</td>
              <td align="center" rowspan="1" colspan="1">34</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn>
            <p>SPAP: systolic pulmonary artery pressure.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>In the immunological evaluation of the patient, the immune panel (HLA I/II using the
Luminex&#xAE; method) changed from 0%/0% before VAD implantation to 0%/23% after
implantation. After inclusion in the HT list, the patient developed signs of
inflammation in the subxiphoid region. Because the VAD infection did not resolve with
antibiotic therapy, the patient was prioritized for HT, to avoid VAD-associated
complications. Approximately 14 months after implantation, the patient underwent HT
successfully without acute rejection or graft dysfunction. However, he had infectious
complications and reversible acute renal failure, and he was discharged 75 days after
the procedure. At present, the patient is on outpatient care, with a good functional
status.</p>
    </sec>
    <sec sec-type="discussion">
      <title>Discussion</title>
      <p>The INTERMACS database has reported the implantation of approximately 7,000 VADs
worldwide since 2006; in addition, after 2010, the number of annual implants has
increased 10&#xA0;times in comparison with the first registration years<sup><xref rid="r04" ref-type="bibr">4</xref>,<xref rid="r05" ref-type="bibr">5</xref></sup>.
To the best of our knowledge, this is the first report of a patient discharge in Brazil
after VAD implantation and subsequent HT. The first case of mechanical circulatory
support in Brazil was reported in 1994, when a patient with Chagas cardiomyopathy
received a ventricular assist device as a bridge to transplant<sup><xref rid="r06" ref-type="bibr">6</xref></sup>.</p>
      <p>Indwelling devices are indicated for the following situations (i) long-term strategic
planning for patients eligible for HT (bridge to transplantation), aiming at improving
the functionality of VADs and the patient&#x2019;s quality of life, in comparison with those
with a long waiting period in the transplantation list; (ii) in patients in whom HT
benefits are uncertain or marginal (bridge to application); (iii) as definitive therapy
for those who are not candidates or in case of HT unavailability<sup><xref rid="r07" ref-type="bibr">7</xref></sup>.</p>
      <p>The first indwelling devices introduced into clinical practice were pulsatile. The
REMATCH Trial randomly selected 129 patients, with HF NYHA class IV and ineligible for
HT, to receive the HeartMate XVE&#x2122; device or remain on standard drug therapy. The
implantation of the device yielded a 48% decrease in the risk of death within 1 year
after implantation<sup><xref rid="r08" ref-type="bibr">8</xref></sup>. The HeartMate II
trial randomly selected 200&#xA0;patients, with advanced HF and ineligible for HT, to receive
continuous flow or pulsatile flow devices. The 2-year survival rates in the pulsatile
and continuous flow groups were 24% and 58%, respectively<sup><xref rid="r09" ref-type="bibr">9</xref></sup>.</p>
      <p>At present, most VAD implants serve as a bridge to HT in patients with cardiogenic shock
who require inotropic agents and in those who are either clinically stable (INTERMACS
classification 3) or have progressive clinical worsening (INTERMACS classification 2).
However, in recent years, we have observed a progressive increase in the number of
implants in less-severe patients and as definitive therapy for those ineligible for
HT<sup><xref rid="r04" ref-type="bibr">4</xref></sup>.</p>
      <p>The patient described in the present case report was initially considered as a candidate
for VAD implantation because of PH and important contraindications to HT. However, after
120&#xA0;days of implantation, there was a significant decrease in PAP values, which reached
levels close to normal. This decrease in pulmonary pressures in patients who underwent
VAD implantation has been previously described, and some authors advocate the use of VAD
therapy to decrease the pulmonary pressure on potential HT candidates with PH<sup><xref rid="r10" ref-type="bibr">10</xref></sup>.</p>
      <p>Despite the immunological sensitization after VAD implantation, there were no acute
rejections after HT. The transfusions of blood products after implantation may be
related to the post-procedure sensitization; however, a correlation between VAD
implantation and alloimmunization may exist<sup><xref rid="r11" ref-type="bibr">11</xref></sup>. This case shows that VAD implantation is feasible in Brazilian
patients with advanced HF who are contraindicated for HT. Initial PH did not affect
implantation outcomes, and the subsequent normalization of PAP led to successful HT.</p>
      <p>In Brazil, the number of VAD implants is substantially lower than that in the United
States and Europe. Despite evidence of improved survival and quality of life in patients
who underwent VAD implantation, the direct and indirect costs of this therapy are still
high and the procedure is not free of complications. Therefore, an evaluation of
cost-effectiveness is necessary for the careful selection of patients who would benefit
from this therapy, considering the nascent use of VADs in Brazil.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="con">
        <p>
          <bold>Author contributions</bold>
        </p>
        <p>Conception and design of the research: Biselli B, Ayub- Ferreira SM, Avila MS,
Gaiotto FA, Jatene FB, Bocchi EA; Acquisition of data: Biselli B, Ayub-Ferreira SM,
Avila MS, Gaiotto FA, Jatene FB, Bocchi EA; Analysis and interpretation of the data:
Biselli B, Ayub-Ferreira SM, Avila MS, Gaiotto FA, Jatene FB, Bocchi EA; Writing of
the manuscript: Biselli B, Ayub-Ferreira SM, Bocchi EA; Critical revision of the
manuscript for intellectual content: Biselli B, Ayub-Ferreira SM, Avila MS, Gaiotto
FA, Jatene FB, Bocchi EA.</p>
      </fn>
      <fn fn-type="conflict">
        <p>
          <bold>Potential Conflict of Interest</bold>
        </p>
        <p>No potential conflict of interest relevant to this article was reported.</p>
      </fn>
      <fn fn-type="supported-by">
        <p>
          <bold>Sources of Funding</bold>
        </p>
        <p>There were no external funding sources for this study.</p>
      </fn>
      <fn fn-type="other">
        <p>
          <bold>Study Association</bold>
        </p>
        <p>This study is not associated with any thesis or dissertation work.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="r01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bocchi</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Marcondes-Braga</surname>
              <given-names>FG</given-names>
            </name>
            <name>
              <surname>Ayub-Ferreira</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Rohde</surname>
              <given-names>LE</given-names>
            </name>
            <name>
              <surname>Oliveira</surname>
              <given-names>WA</given-names>
            </name>
            <name>
              <surname>Almeida</surname>
              <given-names>DR</given-names>
            </name>
            <etal/>
            <collab>Sociedade Brasileira de Cardiologia</collab>
          </person-group>
          <article-title>III Diretriz brasileira de insufici&#xEA;ncia card&#xED;aca
cr&#xF4;nica</article-title>
          <source>Arq Bras Cardiol</source>
          <year>2009</year>
          <volume>93</volume>
          <issue>1</issue>
          <supplement>supl.1</supplement>
          <fpage>1</fpage>
          <lpage>71</lpage>
          <pub-id pub-id-type="pmid">19838462</pub-id>
        </element-citation>
      </ref>
      <ref id="r02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Braunwald</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Heart failure</article-title>
          <source>JACC Heart Failure</source>
          <year>2013</year>
          <volume>1</volume>
          <issue>1</issue>
          <fpage>1</fpage>
          <lpage>20</lpage>
          <pub-id pub-id-type="pmid">24621794</pub-id>
        </element-citation>
      </ref>
      <ref id="r03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bacal</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Souza-Neto</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Fiorelli</surname>
              <given-names>AI</given-names>
            </name>
            <name>
              <surname>Mejia</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Marcondes-Braga</surname>
              <given-names>FG</given-names>
            </name>
            <name>
              <surname>Mangini</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>II Diretriz brasileira de transplante card&#xED;aco</article-title>
          <source>Arq Bras Cardiol</source>
          <year>2009</year>
          <volume>94</volume>
          <issue>1</issue>
          <supplement>supl. 1</supplement>
          <fpage>e16</fpage>
          <lpage>e73</lpage>
          <pub-id pub-id-type="pmid">20625634</pub-id>
        </element-citation>
      </ref>
      <ref id="r04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kirklin</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Naftel</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Kormos</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Stevenson</surname>
              <given-names>LW</given-names>
            </name>
            <name>
              <surname>Pagani</surname>
              <given-names>FD</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>MA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Fifth INTERMACS annual report: risk factor analysis from more than
6,000 mechanical circulatory support patients</article-title>
          <source>J Heart Lung Transplant</source>
          <year>2013</year>
          <volume>32</volume>
          <issue>2</issue>
          <fpage>141</fpage>
          <lpage>156</lpage>
          <pub-id pub-id-type="pmid">23352390</pub-id>
        </element-citation>
      </ref>
      <ref id="r05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stewart</surname>
              <given-names>GC</given-names>
            </name>
            <name>
              <surname>Stevenson</surname>
              <given-names>LW</given-names>
            </name>
          </person-group>
          <article-title>Keeping left ventricular assist device acceleration on
track</article-title>
          <source>Circulation</source>
          <year>2011</year>
          <volume>123</volume>
          <issue>14</issue>
          <fpage>1559</fpage>
          <lpage>1568</lpage>
          <pub-id pub-id-type="pmid">21482974</pub-id>
        </element-citation>
      </ref>
      <ref id="r06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bocchi</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Vieira</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Fiorelli</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hayashida</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Mayzato</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Leirner</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Perfil hemodin&#xE2;mico e neuro-hormonal durante assist&#xEA;ncia circulat&#xF3;ria
com ventr&#xED;culo artificial heterot&#xF3;pico seguida de transplante
card&#xED;aco</article-title>
          <source>Arq Bras Cardiol</source>
          <year>1994</year>
          <volume>62</volume>
          <issue>1</issue>
          <fpage>23</fpage>
          <lpage>27</lpage>
          <pub-id pub-id-type="pmid">8010894</pub-id>
        </element-citation>
      </ref>
      <ref id="r07">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Feldman</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Pamboukian</surname>
              <given-names>SV</given-names>
            </name>
            <name>
              <surname>Teuteberg</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Birks</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Lietz</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Moore</surname>
              <given-names>SA</given-names>
            </name>
            <etal/>
            <collab>International Society for Heart and Lung Transplantation</collab>
          </person-group>
          <article-title>The 2013 International Society for Heart and Lung Transplantation
Guidelines for mechanical circulatory support: executive summary</article-title>
          <source>J Heart Lung Transplant</source>
          <year>2013</year>
          <volume>32</volume>
          <issue>2</issue>
          <fpage>157</fpage>
          <lpage>187</lpage>
          <pub-id pub-id-type="pmid">23352391</pub-id>
        </element-citation>
      </ref>
      <ref id="r08">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rose</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Gelijns</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Moskowitz</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Heitjan</surname>
              <given-names>DF</given-names>
            </name>
            <name>
              <surname>Stevenson</surname>
              <given-names>LW</given-names>
            </name>
            <name>
              <surname>Dembitsky</surname>
              <given-names>W</given-names>
            </name>
            <etal/>
            <collab>Randomized Evaluation of Mechanical Assistance for the Treatment of
Congestive Heart Failure Study Group</collab>
          </person-group>
          <article-title>Long-term use of a left ventricular assist device for end-stage heart
failure</article-title>
          <source>N Engl J Med</source>
          <year>2001</year>
          <volume>345</volume>
          <issue>20</issue>
          <fpage>1435</fpage>
          <lpage>1443</lpage>
          <pub-id pub-id-type="pmid">11794191</pub-id>
        </element-citation>
      </ref>
      <ref id="r09">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Slaughter</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Rogers</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Milano</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Russell</surname>
              <given-names>SD</given-names>
            </name>
            <name>
              <surname>Conte</surname>
              <given-names>JV</given-names>
            </name>
            <name>
              <surname>Feldman</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
            <collab>HeartMate II Investigators</collab>
          </person-group>
          <article-title>Advanced heart failure treated with continuous-flow left ventricular
assist device</article-title>
          <source>N Engl J Med</source>
          <year>2009</year>
          <volume>361</volume>
          <issue>23</issue>
          <fpage>2241</fpage>
          <lpage>2251</lpage>
          <pub-id pub-id-type="pmid">19920051</pub-id>
        </element-citation>
      </ref>
      <ref id="r10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Beyersdorf</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Schlensak</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Berchtold-Herz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Trummer</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Regression of "fixed" pulmonary vascular resistance in heart
transplant candidates after unloading with ventricular assist
devices</article-title>
          <source>J Thorac Cardiovasc Surg</source>
          <year>2010</year>
          <volume>140</volume>
          <issue>4</issue>
          <fpage>747</fpage>
          <lpage>749</lpage>
          <pub-id pub-id-type="pmid">20850652</pub-id>
        </element-citation>
      </ref>
      <ref id="r11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Urban</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gazdic</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Slimackova</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Pirk</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Szarszoi</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Maly</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Alloimmunosensitization in left ventricular assist device recipients
and impact on posttransplantation outcome</article-title>
          <source>ASAIO J</source>
          <year>2012</year>
          <volume>58</volume>
          <issue>6</issue>
          <fpage>554</fpage>
          <lpage>561</lpage>
          <pub-id pub-id-type="pmid">23069898</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
